Find us on:Our Company
Innovative, Insightful Facility and Team that is Committed to Delivering Results
News
April 22, 2013 - Gallus BioPharmaceuticals Presents Real World Date From Its "Factory of the Future"
February 26, 2013 - Gallus BioPharmaceuticals Announces Addition of Senior Industry Leader to Its Board of Directors
January 22, 2013 - Gallus BioPharmaceuticals announces a new collaboration with Refine Technologies to optimize continuous cell culture processes.
October 24, 2012 - Mediomics LLC Receives Phase II SBIR Contract: Awarded $997,251 to Develop New In-Process Analyzer for Biologics
September 18, 2012 - Gallus BioPharmaceuticals and Roslin Cells Announce an Exclusive Partnership to Supply Cell Therapies for Clients
August 14, 2012 - Gallus BioPharmaceuticals Announces Collaboration Agreement with Natrix Separations Inc.
May 24, 2012 - Gallus BioPharmaceuticals Completes Initial $20 Million Expansion of Early-Phase Clinical Manufacturing Facility
May 15, 2012 - Gallus BioPharmaceuticals's Virtual Ownership Model Thrives with SAP Business All in One
Upcoming Events
May 14-15, 2013 - Progressive Clinical Manufacturing Outsourcing - Hamburg, Germany
May 21-23, 2013 - 2. May 21 – 23, 2013 –BIOPHORUM - Cambridge, Massachusetts
June 3-5, 2013 - IBC Single-Use Applications for Biopharmaceutical Manufacturing
Mark R. Bamforth
President and CEO
Mark Bamforth is the President and CEO of Gallus Biopharmaceuticals. Mark founded Gallus in 2010 in order to establish the premier contract manufacturer of commercial bulk biologics with a team which is currently delivering commercial products to patients in over 50 countries from an approved facility in the USA.
In this leadership role, Mark draws upon his extensive experience of assembling talented teams to build and operate manufacturing plants around the world as well as his business experience as a Corporate Officer and business leader at Genzyme Corporation during a period of rapid growth.
Mark was SVP for Corporate Operations and Pharmaceuticals at Genzyme Corporation with responsibility for 12 manufacturing sites in USA and Europe with 3600 staff. During the past decade he oversaw a 200% growth in operations with the investment of over $2B in multiple technologies for manufacturing and infrastructure as Genzyme grew organically and through acquisitions.
Additionally, Mark was responsible for the Pharmaceutical business which delivered a doubling in revenue over 5 years by performing contract manufacturing of peptides, lipids, custom materials and drug delivery technologies to the pharmaceutical industry and manufacturing materials for internal drug programs.
Prior to joining Genzyme in 1988, Mark was a chemical engineer in the Scottish whisky industry where he led a JV biotech project to produce a nutraceutical from algae and designed and operated a patented photo-bioreactor.
Mark began his career exploring and producing oil in the hostile waters of the North Sea.
Mark serves on the MassBio Board, representing the biotech industry in MA, and has served on advisory boards for University College London's school of Biochemical Engineering and on Scottish Enterprise's International Advisory Board. Mark is a Founding Trustee of a charity, the Saltire Foundation, which offers young Scottish entrepreneurs the opportunity to experience and learn in high growth companies in the USA and beyond.
Mark has a BS in Chemical Engineering from Strathclyde University, Glasgow, and an MBA from Henley Business School.